Glaxo Operations UK Ltd.

Primary objective: To evaluate the effectiveness of belimumab compared with placebo on standard treatment in slowing the decline of lung volume in DCSSC-ILD subjects Key secondary objectives: To evaluate the effectiveness of belimumab compared with placebo on standard treatment in reducing the degree of skin thickening at week 52 in DCSSC-ILD subjects To evaluate the effectiveness of belimumab compared with placebo on standard treatment in reducing fatigue in DCSSC-ILD subjects. To evaluate the effectiveness of belimumab compared with placebo on standard treatment in slowing the progression of SSC or reducing mortality in DCSSC-ILD subjects

1) Primary objective (pharmacokinetics): To evaluate the exposure of belimumab after administration of 200 mg SC belimumab in Chinese pediatric SLE subjects who had previously received belimumab IV treatment; 2) Secondary objective (safety): To evaluate the safety and tolerability of 200 mg SC belimumab in pediatric SLE subjects who had previously received belimumab IV treatment.

The aim of this study was to evaluate the rwORR of dabrafenib plus trametinib in Chinese patients with unresectable or metastatic BRAF V600 mutation-positive mucosal melanoma and Chinese patients with nonmucosal melanoma (cutaneous and acral melanoma), regardless of the use of new antineoplastic therapy or concomitant drug therapy.